July 20, 2024

Companion Diagnostics Market Size To Cross USD 16.8 Bn By 2030

The global companion diagnostics market size accounted for US$ 8.59  Bn in 2022 and is projected to reach around USD 16.8  Bn by 2030, growing at a CAGR of 8.74% from 2022 to 2030.

Companion Diagnostics Market Size 2022 To 2030

Report Summary

The global companion diagnostics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the companion diagnostics market across the globe.

A comprehensive estimate on the companion diagnostics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of companion diagnostics during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2457

Companion Diagnostics Market Report Scope

Report CoverageDetails
Market Size in 2022USD 8.59 Billion
Market Size by 2030USD 16.8 Billion
Growth Rate from 2022 to 2030CAGR of 8.74%
Base Year2021
Forecast Period2022 to 2030
Segments Covered
  • By Indication
  • By Product & Service
  • By Technology
  • By Indication
  • By End-User

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized companion diagnostics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read:  Copper Sputtering Target Market Size Analysis 2022 To 2030

Companion Diagnostics Market Players

The report includes the profiles of key companion diagnostics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Agilent Technologies, Inc. (US)
  • Qiagen N.V. (Germany)
  • Thermo Fisher Scientific, Inc. (US)
  • Abbott Laboratories, Inc. (US)

Market Segmentation

By Indication

  • Cancer
    • Lung Cancer
    • Breast Cancer
    • Blood Cancer
    • Colorectal Cancer
    • Other Cancer Types
  • Neurological Disorders
  • Cardiovascular Diseases
  • Infectious Diseases
  • Other Indications

By Product & Service

  • Assays, Kits & Reagents
  • Software & Services

By Technology

  • Polymerase Chain Reaction
  • Next-generation Sequencing
  • In Situ Hybridization
  • Immunohistochemistry
  • Other

By Indication

  • Oncology
  • Neurology
  • Infectious Diseases
  • Others

By End-User

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • Contract Research Organizations
  • Other End Users

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Companion Diagnostics Market 

5.1. COVID-19 Landscape: Companion Diagnostics Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Companion Diagnostics Market, By Indication

8.1. Companion Diagnostics Market, by Indication, 2022-2030

8.1.1. Cancer

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Neurological Disorders

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Cardiovascular Diseases

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Infectious Diseases

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Other Indications

8.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Companion Diagnostics Market, By Product & Service

9.1. Companion Diagnostics Market, by Product & Service, 2022-2030

9.1.1. Assays, Kits & Reagents

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Software & Services

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Companion Diagnostics Market, By Technology 

10.1. Companion Diagnostics Market, by Technology, 2022-2030

10.1.1. Polymerase Chain Reaction

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Next-generation Sequencing

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. In Situ Hybridization

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Immunohistochemistry

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Other

10.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Companion Diagnostics Market, By Indication

11.1. Companion Diagnostics Market, by Indication, 2022-2030

11.1.1. Oncology

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Neurology

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Infectious Diseases

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Others

11.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Companion Diagnostics Market, By End-User

12.1. Companion Diagnostics Market, by End-User, 2022-2030

12.1.1. Pharmaceutical & Biopharmaceutical Companies

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Reference Laboratories

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Contract Research Organizations

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Other End Users

12.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Companion Diagnostics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Indication (2017-2030)

13.1.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.1.3. Market Revenue and Forecast, by Technology (2017-2030)

13.1.4. Market Revenue and Forecast, by Indication (2017-2030)

13.1.5. Market Revenue and Forecast, by End-User (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Indication (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Technology (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Indication (2017-2030)

13.1.6.5. Market Revenue and Forecast, by End-User (2017-2030)

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Indication (2017-2030)

13.1.7.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.1.7.3. Market Revenue and Forecast, by Technology (2017-2030)

13.1.7.4. Market Revenue and Forecast, by Indication (2017-2030)

13.1.7.5. Market Revenue and Forecast, by End-User (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Indication (2017-2030)

13.2.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.2.3. Market Revenue and Forecast, by Technology (2017-2030)

13.2.4. Market Revenue and Forecast, by Indication (2017-2030)

13.2.5. Market Revenue and Forecast, by End-User (2017-2030)

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Indication (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Technology (2017-2030)

13.2.7. Market Revenue and Forecast, by Indication (2017-2030)

13.2.8. Market Revenue and Forecast, by End-User (2017-2030)

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Indication (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Technology (2017-2030)

13.2.10. Market Revenue and Forecast, by Indication (2017-2030)

13.2.11. Market Revenue and Forecast, by End-User (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Indication (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.2.12.3. Market Revenue and Forecast, by Technology (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Indication (2017-2030)

13.2.13. Market Revenue and Forecast, by End-User (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Indication (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.2.14.3. Market Revenue and Forecast, by Technology (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Indication (2017-2030)

13.2.15. Market Revenue and Forecast, by End-User (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Indication (2017-2030)

13.3.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.3.3. Market Revenue and Forecast, by Technology (2017-2030)

13.3.4. Market Revenue and Forecast, by Indication (2017-2030)

13.3.5. Market Revenue and Forecast, by End-User (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Indication (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Technology (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Indication (2017-2030)

13.3.7. Market Revenue and Forecast, by End-User (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Indication (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Technology (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Indication (2017-2030)

13.3.9. Market Revenue and Forecast, by End-User (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Indication (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.3.10.3. Market Revenue and Forecast, by Technology (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Indication (2017-2030)

13.3.10.5. Market Revenue and Forecast, by End-User (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Indication (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.3.11.3. Market Revenue and Forecast, by Technology (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Indication (2017-2030)

13.3.11.5. Market Revenue and Forecast, by End-User (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Indication (2017-2030)

13.4.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.4.3. Market Revenue and Forecast, by Technology (2017-2030)

13.4.4. Market Revenue and Forecast, by Indication (2017-2030)

13.4.5. Market Revenue and Forecast, by End-User (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Indication (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.4.6.3. Market Revenue and Forecast, by Technology (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Indication (2017-2030)

13.4.7. Market Revenue and Forecast, by End-User (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Indication (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Technology (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Indication (2017-2030)

13.4.9. Market Revenue and Forecast, by End-User (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Indication (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.4.10.3. Market Revenue and Forecast, by Technology (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Indication (2017-2030)

13.4.10.5. Market Revenue and Forecast, by End-User (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Indication (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.4.11.3. Market Revenue and Forecast, by Technology (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Indication (2017-2030)

13.4.11.5. Market Revenue and Forecast, by End-User (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Indication (2017-2030)

13.5.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.5.3. Market Revenue and Forecast, by Technology (2017-2030)

13.5.4. Market Revenue and Forecast, by Indication (2017-2030)

13.5.5. Market Revenue and Forecast, by End-User (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Indication (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Technology (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Indication (2017-2030)

13.5.7. Market Revenue and Forecast, by End-User (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Indication (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Product & Service (2017-2030)

13.5.8.3. Market Revenue and Forecast, by Technology (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Indication (2017-2030)

13.5.8.5. Market Revenue and Forecast, by End-User (2017-2030)

Chapter 14. Company Profiles

14.1. F. Hoffmann-La Roche Ltd. (Switzerland)

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Agilent Technologies, Inc. (US)

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Qiagen N.V. (Germany)

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Thermo Fisher Scientific, Inc. (US)

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Abbott Laboratories, Inc. (US)

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com